Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state · people with psychosis
1 finding from 1 review
Global state: 1. General ‐ no clinically significant improvement ‐ short term < 30% improvement on BPRS · people with psychosis
Any antiglucocorticoid may leads to lower global state: 1. General ‐ no clinically significant improvement ‐… compared with placebo (low certainty).
1 finding from 1 review
Global state: 2. Specific: positive ‐ no clinically significant improvement ‐ short term (< 50% improvement on BPRS PSS) · people with psychosis
Any antiglucocorticoid may leads to lower global state: 2. Specific: positive ‐ no clinically significant… compared with placebo (low certainty).
1 finding from 1 review
Global state: improvement, short term PANSS · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in global state: improvement, short term PANSS compared with placebo (low certainty).
1 finding from 1 review
Mental state: General ‐ average total score (PANSS, high = poor) ‐ up to 12 weeks (short‐term) · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
General functioning ‐ short term GAS · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in leaving the study early, short term compared with placebo (moderate certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
CHLORPROMAZINE may leads to higher no significant clinical response: short term (up to 6 months) compared with OLANZAPINE (low certainty).
1 finding from 1 review
QoL · patients with schizophrenia
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in no significant clinical response: short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
CHLORPROMAZINE may leads to higher adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with QUETIAPINE (low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
1 finding from 1 review
Mental state: General ‐ average endpoint score (BPRS, high score = poor) ‐ medium term ( · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Health‐related quality of life (physical) · patients with schizophrenia
1 finding from 1 review